Inhibitor rates

Your body can also make antibodies called "inhibitors," against Kogenate FS, which may stop Kogenate FS from working properly.

Several studies looked at the inhibitor rates of Kogenate® FS Antihemophilic Factor (Recombinant).

Previously Untreated Patients Inhibitor Registry Data

Post marketing registries in previously untreated patients taking Kogenate FS have shown inhibitor development rates of 31-50% which is comparable to previously-reported inhibitor rates for FVIII products. Some of these registries showed a trend towards an increased risk of inhibitor development in PUPs taking Kogenate FS, as compared to another rFVIII product.3

In clinical studies of PUPs and MTPs (N=60), 15% of patients (9 of 60) developed inhibitors2*

*In clinical trials with PUPs and MTPs, 88% of patients (53 of 60) achieved 20 or more exposure days.

In a clinical study of patients (N=64), 12.5% of patients (8 of 64) developed de novo inhibitors in the Joint Outcome Study1

†2 patients developed high-titer (>5 BU) inhibitors and were withdrawn from the study.1

Product safety and quality – from the start

Our manufacturing process exemplifies Bayer's dedication to the quality and safety of your treatment – from fermentation to purification to filling and freeze drying to packaging.

Learn about our manufacturing process

Your Bayer Rep is here to help

Get support.
Be connected.

Our support program is designed to connect you to people, resources, and personalized information related to hemophilia A.

Sign up now

Your treatment for the adventures ahead.

Learn more